Search

cobas® KRAS Mutation Test

KRAS Mutation Test

Identifies mutations in codons 12, 13 and 61 of the KRAS gene

The cobas® KRAS Mutation Test offers broad mutation coverage of KRAS codons 12, 13 and 61 to identify colorectal cancer patients who are not likely to respond to anti-EGFR monoclonal antibody therapies.

Features and benefits

  • The cobas® KRAS Mutation Test detects major mutations in codons 12, 13 and 61 from colorectal cancer patients
  • In formalin-fixed, paraffin-embedded tissue (FFPET), the cobas® KRAS Mutation Test can detect <5% mutant sequence copies in a background of wild-type DNA
  • Robust, reliable KRAS test results can be obtained from a single, 5µm FFPET section with >10% tumor content using the cobas® KRAS Mutation Test
  • The test can be performed in <8 hours so results can be reported to the treating physician within a few days from laboratory receipt of specimen
  • Liquid, ready-to-use reagents increase laboratory efficiency
  • Automated result interpretation and test reporting provides consistent, objective and reproducible results from laboratory to laboratory
Contact Us
Intended use

Intended use

The cobas® KRAS Mutation Test, for use with the cobas® 4800 System, is a real-time PCR test for the detection of somatic mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer (CRC) tumor tissue. The test is intended to be used as an aid in the identification of CRC patients who should not be treated with Erbitux® (cetuximab) or with Vectibix® (panitumumab) when KRAS Codon 12 or 13 mutation is detected. Safety and efficacy of Erbitux® (cetuximab) or Vectibix® (panitumumab) have not been established in patients whose tumors have Codon 61 mutation. Specimens are processed using the cobas® DNA Sample Preparation Kit for manual sample preparation and the cobas z 480 analyzer for automated amplification and detection.

 

The cobas® KRAS Mutation Test detects the following KRAS mutations.

 

 Codon Mutation ID 
  AA Change
 COSMIC ID
 12   c.34G>T
    12C
   516
 12   c.34G>A
    12S   517
 12   c.34G>C
    12R
   518
 12   c.35G>T
    12V
   520
 12   c.35G>A
    12D
   521
 12   c.35G>C
    12A
   522
 13   c.38G>A
    13D
   532
 61   c.181C>A
    61K
   549
 61   c.181C>G
    61E
   550
 61   c.182A>C
    61P
   551
 61   c.182A>G
    61R
   552
 61    c.182A>T
    61L
   553
 61   c.183A>C
    61Hc
   554
 61   c.183A>T
    61Ht
   555

Registration status

US-IVD

Related diseases

Related assays

Product image for cobas® DNA Sample Preparation Kit
cobas® DNA Sample Preparation Kit
cobas® 4800 BRAD V600 Mutation Test
cobas® 4800 BRAF V600 Mutation Test
RMD_cobas_EGFR_Mutation_Test_v2
cobas® EGFR Mutation Test v2
IVD For in vitro diagnostic use.
INFORM HER2 Dual ISH DNA Probe Cocktail Assay
INFORM HER2 Dual ISH DNA Probe Cocktail Assay To determine HER2 gene status by enumeration of the ratio of the HER2 gene to Chromosome 17.
IVD For in vitro diagnostic use.
VENTANA<sup>®</sup> anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody
VENTANA® anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody For use with VENTANA MMR RxDx Panel and the VENTANA MMR IHC Panel, US-FDA For the qualitative immunohistochemistry test intended for use in the assessment of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) in formalin-fixed, paraffin-embedded (FFPE) tissue specimens by light microscopy.
Roche Pathway HER2 4B5 assay slide and therapy image
PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (FDA approved)

Related systems

cobas® 4800 System

Highly efficient, flexible workflows and a consolidated assay menu deliver confidence with every result. Automated PCR setup and analysis help make the most of your resources and reduce error.

More
cobas® 4800 System